Medical Pharmacology Question Bank

Chapter 2: Pharmacokinetics — Module 3: Metabolism and Excretion
Tier: Core Concepts (CC)

BEFORE YOU BEGIN

These Core Concepts questions cover drug elimination — the metabolic and excretory processes that remove drugs from the body and determine how long their effects last. You will work through questions on Phase I and Phase II hepatic metabolism, the CYP450 enzyme system with emphasis on CYP3A4 and CYP2D6, enzyme induction and inhibition interactions with specific clinical examples, hepatic extraction ratio and the clinical implications for drug design, renal elimination through glomerular filtration, active tubular secretion, and passive reabsorption, creatinine clearance as a GFR surrogate, Michaelis-Menten kinetics and zero-order elimination, enterohepatic recirculation, and the integrated pharmacokinetic consequences of hepatic and renal failure. This module completes the full ADME framework established across the three pharmacokinetics modules. Work through each question before reading the rationale.

1. Hepatic drug metabolism is conventionally divided into Phase I and Phase II reactions. Which of the following correctly distinguishes these two phases and identifies the primary enzymatic system responsible for Phase I oxidation?

A) Phase I reactions conjugate drug molecules with endogenous polar groups such as glucuronate, sulfate, or glutathione to increase water solubility — the primary enzymes are UDP-glucuronosyltransferases located in the hepatocyte cytoplasm; Phase II reactions introduce functional groups via oxidation and reduction using the cytochrome P450 system
B) Phase I and Phase II reactions are functionally interchangeable — the designation refers only to whether the reaction occurs before or after biliary excretion, and both phases use identical enzyme systems located in the hepatocyte nucleus
C) Phase I reactions occur exclusively in the kidney proximal tubule and convert lipophilic drugs to water-soluble glucuronides for urinary excretion — Phase II reactions occur in the liver and introduce reactive functional groups that are then conjugated in Phase I
D) Phase I reactions are saturable and follow zero-order kinetics at all therapeutic drug concentrations — Phase II conjugation reactions are non-saturable and follow first-order kinetics regardless of drug concentration
E) Phase I reactions introduce or unmask functional groups through oxidation, reduction, or hydrolysis — primarily via the cytochrome P450 (CYP) enzyme system in the hepatocyte smooth endoplasmic reticulum; Phase II reactions conjugate these functional groups with endogenous molecules to increase water solubility and prepare the drug for excretion

ANSWER: E

Rationale:

Hepatic metabolism is organized into two functionally distinct phases. Phase I reactions modify the drug molecule by introducing or unmasking a polar functional group — typically through oxidation (most common), reduction, or hydrolysis. The cytochrome P450 (CYP) enzyme superfamily, housed in the smooth endoplasmic reticulum of hepatocytes, is responsible for the vast majority of Phase I oxidative reactions. Phase I metabolites are more polar than the parent compound but are not necessarily pharmacologically inactive — they may be active (as with codeine conversion to morphine via CYP2D6), inactive, or more toxic than the parent drug. Phase II reactions then conjugate the Phase I metabolite — or the parent drug directly if it already possesses a suitable functional group — with an endogenous polar molecule: glucuronic acid (via UDP-glucuronosyltransferases, or UGTs), sulfate, glutathione, acetyl groups, or methyl groups. Conjugation greatly increases water solubility and typically renders the metabolite pharmacologically inactive, facilitating biliary or renal excretion. Not all drugs require both phases — some proceed directly to Phase II conjugation without prior Phase I modification.

2. The cytochrome P450 enzyme CYP3A4 is the most abundant hepatic CYP isoform and metabolizes approximately 50% of clinically used drugs. Which of the following statements about CYP3A4 is correct?

A) CYP3A4 is expressed exclusively in hepatocytes — intestinal CYP3A4 does not contribute to drug metabolism because the intestinal epithelium lacks the NADPH-cytochrome P450 reductase cofactor required for CYP activity
B) CYP3A4 is a constitutively expressed enzyme with fixed activity — its expression cannot be increased or decreased by drug exposure, diet, or disease, making CYP3A4-mediated interactions predictable from drug structure alone without clinical monitoring
C) CYP3A4 is expressed in both hepatocytes and intestinal enterocytes, is inducible by drugs such as rifampin and carbamazepine and inhibitable by drugs such as ketoconazole and clarithromycin, and metabolizes a broad and structurally diverse range of substrate drugs — making it the single most important source of CYP-mediated drug interactions in clinical practice
D) CYP3A4 metabolizes only lipophilic drugs with molecular weights above 400 daltons — small hydrophilic drugs are exclusively metabolized by CYP2D6 and CYP2C9, which have narrower but complementary substrate specificities
E) CYP3A4 activity is genetically fixed and shows the same bimodal poor metabolizer/extensive metabolizer polymorphism as CYP2D6 — patients can be reliably genotyped to predict CYP3A4 drug interactions before prescribing

ANSWER: C

Rationale:

CYP3A4 is clinically dominant for several reasons. It is the most abundant CYP isoform in both liver and small intestinal enterocytes, meaning it contributes to both hepatic first-pass metabolism and intestinal wall metabolism of oral drugs. Its substrate specificity is remarkably broad — it accepts an enormous structural diversity of drugs including benzodiazepines, statins, calcium channel blockers, immunosuppressants, HIV protease inhibitors, many antibiotics, and antifungals. CYP3A4 is highly inducible: rifampin, carbamazepine, phenytoin, and St. John's wort upregulate CYP3A4 expression via the pregnane X receptor (PXR), accelerating metabolism of co-administered substrates and reducing their plasma concentrations to subtherapeutic levels. CYP3A4 is also subject to potent inhibition by azole antifungals (ketoconazole, itraconazole), macrolide antibiotics (clarithromycin, erythromycin), and grapefruit juice furanocoumarins, causing dangerous accumulation of substrate drugs. The combination of high abundance, broad substrate specificity, and susceptibility to both induction and inhibition makes CYP3A4 the most clinically impactful drug-metabolizing enzyme.

3. CYP2D6 is responsible for approximately 25% of CYP-mediated drug metabolism and shows clinically important genetic polymorphism. Which of the following correctly describes the clinical significance of CYP2D6 polymorphism?

A) CYP2D6 poor metabolizers have increased CYP2D6 enzyme activity due to gene duplication — they metabolize CYP2D6 substrates faster than average, requiring higher doses of drugs such as codeine and tamoxifen to achieve therapeutic effect
B) CYP2D6 polymorphism affects only pharmacokinetics, never pharmacodynamics — the clinical consequences of poor versus extensive metabolizer status are identical for all CYP2D6 substrate drugs because receptor sensitivity compensates for differences in plasma drug concentration
C) CYP2D6 ultrarapid metabolizers may fail to respond to codeine analgesia because rapid conversion of codeine to morphine is needed for effect — in fact the risk runs opposite: ultrarapid metabolizers produce morphine so rapidly from codeine that potentially toxic plasma morphine concentrations can occur, while poor metabolizers produce little or no morphine and get no analgesia
D) CYP2D6 poor metabolizers accumulate higher plasma concentrations of CYP2D6 substrates than extensive metabolizers given the same dose — this produces increased drug effect and toxicity risk for drugs such as tricyclic antidepressants, metoprolol, and tramadol, while reducing analgesic efficacy of prodrugs such as codeine that require CYP2D6 activation
E) CYP2D6 genotyping reliably predicts drug response for all CYP2D6 substrates and has replaced therapeutic drug monitoring for tricyclic antidepressants, antipsychotics, and opioids in standard clinical practice worldwide

ANSWER: D

Rationale:

CYP2D6 genetic polymorphism produces a spectrum of metabolizer phenotypes: poor metabolizers (PM, approximately 5-10% of Caucasians) who lack functional enzyme; intermediate metabolizers with reduced activity; extensive metabolizers (EM, the majority) with normal activity; and ultrarapid metabolizers (UM, gene duplication) with markedly increased activity. The clinical consequences depend critically on whether the drug is a direct-acting compound or a prodrug. For direct-acting drugs (tricyclic antidepressants, metoprolol, haloperidol, atomoxetine), poor metabolizers accumulate higher plasma concentrations and are at increased risk of toxicity at standard doses, while ultrarapid metabolizers may fail to achieve therapeutic levels. For prodrugs requiring CYP2D6 activation (codeine → morphine, tramadol → O-desmethyltramadol, tamoxifen → endoxifen), poor metabolizers receive little therapeutic benefit because they cannot generate the active metabolite, while ultrarapid metabolizers may produce dangerously high concentrations of the active form — the FDA has issued warnings about codeine use in ultrarapid metabolizers and in children undergoing tonsillectomy for this reason.

4. A patient taking warfarin for atrial fibrillation is started on rifampin for tuberculosis. Two weeks later, her INR has fallen from 2.5 to 1.2 despite no change in warfarin dose. Which pharmacokinetic mechanism explains this interaction?

A) Rifampin is a potent inhibitor of CYP2C9, the primary enzyme responsible for warfarin metabolism — CYP2C9 inhibition reduces warfarin clearance, causing plasma warfarin concentrations to fall as compensatory renal excretion increases to maintain homeostasis
B) Rifampin chelates warfarin in the gastrointestinal tract, forming an insoluble complex that prevents oral absorption — the reduction in warfarin bioavailability causes plasma concentrations to fall and anticoagulant effect to diminish
C) Rifampin is a potent inducer of CYP2C9 and CYP3A4 via activation of the pregnane X receptor (PXR) — increased CYP enzyme expression accelerates warfarin metabolism, reducing plasma warfarin concentrations and anticoagulant effect; warfarin dose must be substantially increased during rifampin co-administration and carefully reduced again when rifampin is stopped
D) Rifampin displaces warfarin from plasma albumin binding sites, increasing the free warfarin fraction — the displaced free drug is rapidly distributed into peripheral tissues, lowering plasma concentrations and anticoagulant effect without affecting warfarin metabolism
E) Rifampin activates vitamin K-dependent clotting factor synthesis through a direct effect on hepatocyte nuclear receptors, overcoming warfarin's anticoagulant mechanism regardless of warfarin plasma concentration

ANSWER: C

Rationale:

Rifampin is one of the most potent CYP enzyme inducers in clinical use. It activates the pregnane X receptor (PXR), a nuclear receptor that upregulates transcription of CYP3A4, CYP2C9, CYP2C19, and P-glycoprotein, among others. Warfarin is primarily metabolized by CYP2C9 (S-warfarin, the more potent enantiomer) and CYP3A4 (R-warfarin). Rifampin-induced upregulation of both enzymes substantially accelerates warfarin metabolism, reducing plasma warfarin concentrations and anticoagulant effect — the INR falls as clotting factor synthesis resumes. The interaction is clinically severe: warfarin doses may need to be increased by 200-300% during rifampin co-administration. The most dangerous phase is when rifampin is stopped — enzyme induction resolves over 2-4 weeks, and the now-excessive warfarin dose produces markedly supratherapeutic INR and hemorrhage risk if not proactively reduced. This interaction exemplifies why patients on narrow therapeutic index drugs require close monitoring whenever strong enzyme inducers are started or stopped.

5. A patient with HIV is taking simvastatin for hyperlipidemia. His physician adds ritonavir-boosted atazanavir to his regimen. Within weeks he develops severe proximal muscle weakness and markedly elevated creatine kinase. Which pharmacokinetic mechanism best explains this adverse event?

A) Ritonavir is a potent CYP3A4 inducer that accelerates simvastatin metabolism — the resulting elevation in simvastatin metabolites, rather than the parent drug, directly causes skeletal muscle toxicity through mitochondrial dysfunction
B) Atazanavir displaces simvastatin from plasma albumin, dramatically increasing free simvastatin concentrations — the displaced drug accumulates in skeletal muscle where it inhibits mitochondrial coenzyme Q synthesis
C) Ritonavir is a potent CYP3A4 inhibitor — co-administration blocks simvastatin metabolism, causing massive accumulation of simvastatin plasma concentrations and skeletal muscle toxicity (rhabdomyolysis); simvastatin is contraindicated with ritonavir-containing regimens
D) Atazanavir inhibits the hepatic OATP1B1 transporter that normally imports simvastatin acid into hepatocytes for therapeutic effect — reduced hepatic uptake causes simvastatin to accumulate in plasma and redistribute to skeletal muscle
E) Ritonavir induces P-glycoprotein in skeletal muscle capillary endothelium, increasing simvastatin delivery to muscle tissue by pumping drug out of the vascular compartment and into myocytes where it causes direct myotoxicity

ANSWER: C

Rationale:

Ritonavir, even at the low "boosting" doses used in modern antiretroviral regimens, is one of the most potent CYP3A4 inhibitors known — its primary pharmacological role in boosted regimens is precisely this inhibitory effect, which it uses to slow the metabolism of co-administered protease inhibitors and extend their plasma half-lives. Simvastatin is almost entirely dependent on CYP3A4 for its hepatic metabolism. When CYP3A4 is blocked by ritonavir, simvastatin plasma concentrations can rise by 10-20 fold or more. At these elevated concentrations, simvastatin causes skeletal muscle injury through inhibition of mevalonate pathway enzymes needed for mitochondrial coenzyme Q10 synthesis and other essential cellular functions, producing rhabdomyolysis — a potentially fatal condition. The FDA label for simvastatin carries a specific contraindication against co-administration with strong CYP3A4 inhibitors including all HIV protease inhibitors. Pravastatin and rosuvastatin, which are not significantly metabolized by CYP3A4, are the preferred statins in patients receiving CYP3A4-inhibiting antiretroviral regimens.

6. Hepatic clearance (CLH) depends on hepatic blood flow and the intrinsic metabolic capacity of the liver. Drugs are classified as high extraction ratio or low extraction ratio based on how efficiently the liver removes drug from portal blood. Which of the following correctly describes the clinical implication of a high hepatic extraction ratio?

A) High extraction ratio drugs have low oral bioavailability due to extensive first-pass metabolism, and their systemic clearance is limited primarily by hepatic blood flow rather than enzyme capacity — conditions that reduce hepatic blood flow (heart failure, cirrhosis with portosystemic shunting) disproportionately reduce clearance of high-extraction drugs
B) High extraction ratio drugs have high oral bioavailability because the liver efficiently concentrates them in bile for enterohepatic recirculation — reduced hepatic blood flow increases their clearance by prolonging hepatic transit time and allowing more complete metabolic extraction
C) High extraction ratio drugs are unaffected by changes in hepatic blood flow because their clearance is limited entirely by enzyme capacity — only CYP enzyme induction or inhibition, not hemodynamic changes, alters the clearance of high-extraction drugs
D) High extraction ratio drugs require dose reduction in patients with renal impairment because the kidneys compensate for reduced hepatic extraction by increasing renal tubular secretion — renal failure abolishes this compensation and causes drug accumulation
E) High extraction ratio drugs always have low volumes of distribution because efficient hepatic extraction prevents peripheral tissue distribution — the liver acts as a sink that keeps plasma drug concentrations low and drug confined to the central compartment

ANSWER: A

Rationale:

The hepatic extraction ratio (E) is the fraction of drug removed from portal blood during a single pass through the liver. High extraction ratio drugs (E > 0.7) are so efficiently metabolized that essentially all drug presented to the liver is cleared — the rate-limiting step is therefore how much drug arrives per unit time, i.e., hepatic blood flow (approximately 1.5 L/min at rest). For these drugs, CLH ≈ Q (hepatic blood flow). Changes in CYP enzyme activity (induction or inhibition) have relatively little effect on their clearance because even with reduced enzyme activity, most of the drug still gets cleared during each hepatic pass — the bottleneck is flow, not capacity. Conversely, conditions that reduce hepatic blood flow — congestive heart failure reducing cardiac output, cirrhosis causing portosystemic shunting — dramatically reduce clearance of high-extraction drugs. Classic high-extraction drugs include lidocaine, propranolol, morphine, verapamil, and nitroglycerin. Low extraction ratio drugs (E < 0.3), by contrast, are poorly extracted — their clearance is limited by enzyme capacity, so CYP induction or inhibition has large effects but changes in blood flow have little effect.

7. The kidneys eliminate drugs through three processes: glomerular filtration, active tubular secretion, and passive tubular reabsorption. Which of the following correctly describes glomerular filtration as a route of renal drug elimination?

A) Glomerular filtration is an active, energy-dependent process that uses specific transporters to move drug from peritubular capillaries into the tubular lumen — it filters both free and protein-bound drug and is the dominant secretory mechanism for most drugs
B) Glomerular filtration is a passive, non-saturable process driven by hydrostatic pressure — it filters only the free (unbound) fraction of drug from plasma at a rate proportional to the glomerular filtration rate (GFR); protein-bound drug is too large to pass through glomerular pores and is not filtered
C) Glomerular filtration filters all plasma drug including protein-bound fractions because glomerular pores are large enough to accommodate albumin-drug complexes — only drugs with molecular weights above 150,000 daltons are excluded from filtration
D) Glomerular filtration rate is irrelevant to drug elimination for drugs that are more than 80% protein-bound because the filtered load of free drug is negligible — for these drugs, active tubular secretion is the only clinically meaningful route of renal elimination
E) Glomerular filtration is bidirectional — drug filtered into the tubular lumen can be returned to the peritubular capillaries by the same hydrostatic pressure mechanism, making net filtration dependent on the oncotic pressure gradient across the glomerular membrane rather than GFR

ANSWER: B

Rationale:

Glomerular filtration is the first step in renal drug elimination. It is a bulk flow process driven by the net hydrostatic pressure across the glomerular capillary wall — no energy expenditure, no carrier proteins, and no saturation. The glomerular filtration barrier consists of fenestrated capillary endothelium, the glomerular basement membrane, and podocyte foot processes, which together prevent passage of large molecules and albumin while allowing free passage of water, electrolytes, and small molecules including free drug. Because albumin (molecular weight approximately 66,000 daltons) cannot pass the filtration barrier, drug that is bound to albumin is also retained in plasma — only the free (unbound) drug fraction is filtered. The filtered load of drug equals the free plasma concentration multiplied by the GFR. For a highly protein-bound drug (e.g., 99% bound), only 1% of plasma drug is free and filterable, making filtration a quantitatively minor elimination pathway for that drug. Renal clearance by filtration alone = fu × GFR, where fu is the unbound fraction.

8. Active tubular secretion in the renal proximal tubule is an important elimination pathway for many drugs. Which of the following correctly describes the characteristics of this process and its clinical significance?

A) Active tubular secretion is a passive, non-saturable process driven by the electrochemical gradient between peritubular capillaries and the tubular lumen — it moves drug in both directions and does not contribute meaningfully to net drug elimination
B) Active tubular secretion is limited to endogenous molecules such as uric acid and creatinine — exogenous drugs are too structurally diverse to be recognized by renal tubular transporters and are eliminated exclusively by glomerular filtration and passive reabsorption
C) Active tubular secretion requires drug to be in its ionized form — un-ionized lipophilic drugs cannot be secreted and depend entirely on glomerular filtration for renal elimination, while ionized hydrophilic drugs are secreted with 100% efficiency regardless of plasma concentration
D) Active tubular secretion is clinically insignificant because the secretory capacity of the proximal tubule is so large that it is never saturated at therapeutic drug concentrations — competitive inhibition between drugs at renal transporters does not occur at standard clinical doses
E) Active tubular secretion uses energy-dependent carrier proteins — primarily organic anion transporters (OAT) for acidic drugs and organic cation transporters (OCT) for basic drugs — to move drug from peritubular capillary blood into the tubular lumen; it can handle both free and protein-bound drug, is saturable, and is subject to competitive inhibition by other drugs using the same transporter

ANSWER: E

Rationale:

Active tubular secretion in the proximal tubule is a carrier-mediated, energy-dependent process that moves drug from the blood in peritubular capillaries across the basolateral membrane of tubular epithelial cells and then across the apical membrane into the tubular lumen. The organic anion transporter family (OAT1, OAT3) handles acidic drugs and anions including penicillins, NSAIDs, and methotrexate, while the organic cation transporter family (OCT2) handles basic drugs and cations including metformin and many H2 blockers. A clinically important feature is that secretory transporters can extract protein-bound drug from capillary blood — unlike glomerular filtration, tubular secretion is not limited to the free fraction. This means that even highly protein-bound drugs can be efficiently cleared by tubular secretion. Because the process is saturable and uses a finite number of transporter molecules, competitive inhibition between two drugs sharing the same transporter can occur at therapeutic concentrations. The classic example is probenecid inhibiting OAT-mediated penicillin secretion — historically exploited to prolong penicillin action during wartime antibiotic scarcity.

9. Passive tubular reabsorption in the distal nephron is the third component of renal drug elimination. Which of the following correctly explains how urine pH manipulation can be used therapeutically to alter drug elimination?

A) Alkalinizing the urine with sodium bicarbonate increases renal clearance of weak base drugs such as amphetamine by converting them to their ionized form in the tubular lumen — ionized drug cannot be reabsorbed and remains trapped in urine for excretion
B) Acidifying the urine accelerates elimination of weak acid drugs such as salicylate — in acidic urine, weak acids are predominantly un-ionized and therefore membrane-permeable, allowing rapid passive reabsorption back into the bloodstream where hepatic metabolism then completes elimination
C) Alkalinizing the urine increases the renal clearance of weak acid drugs such as salicylate — in alkaline urine, weak acids are predominantly ionized and membrane-impermeable, preventing passive tubular reabsorption and trapping drug in the tubular lumen for excretion; this is the pharmacokinetic basis for sodium bicarbonate treatment in salicylate overdose
D) Urine pH manipulation has no effect on renal drug clearance because passive tubular reabsorption is an active transport process that operates independently of the concentration gradient and ionization state of drug in the tubular lumen
E) Alkalinizing the urine is used to accelerate elimination of weak base drugs by increasing their ionization — the ionized form of weak bases is actively secreted by OAT transporters in the proximal tubule, bypassing the passive reabsorption that would otherwise limit their elimination

ANSWER: C

Rationale:

Passive tubular reabsorption occurs when drug diffuses from the concentrated tubular lumen back across the tubular epithelium into the peritubular capillaries, driven by the concentration gradient that develops as water is reabsorbed. Only un-ionized, lipophilic drug can cross the tubular epithelium by passive diffusion — ionized drug is membrane-impermeable and remains trapped in the tubular lumen. The Henderson-Hasselbalch equation predicts the ionization state of a drug based on its pKa and the local pH. For a weak acid drug in alkaline urine (high pH), the equilibrium shifts toward the ionized form (A⁻) — the drug loses its proton and becomes charged. This ionized form cannot diffuse back across the tubular epithelium and is excreted in urine. In acidic urine, the weak acid is predominantly un-ionized (HA) and is reabsorbed. Urine alkalinization with intravenous sodium bicarbonate is therefore a standard treatment for salicylate overdose, accelerating salicylate excretion by trapping it in the tubular lumen in its ionized form. The same principle in reverse applies to weak bases: acidifying the urine promotes ionization of weak bases, trapping them in the tubular lumen — though urine acidification is now rarely used clinically due to metabolic and renal risks.

10. Creatinine clearance (CrCl) is commonly used as a clinical estimate of glomerular filtration rate for the purpose of renal drug dosing. Which of the following correctly describes the relationship between renal function, drug clearance, and dose adjustment?

A) Creatinine clearance overestimates GFR in all patients because creatinine is actively secreted by the proximal tubule in addition to being filtered — the secretory component means creatinine clearance is always higher than true GFR, and drug doses should therefore be reduced below the creatinine clearance-based recommendation
B) For drugs eliminated primarily by renal excretion, clearance falls proportionally as GFR declines — the maintenance dose or dosing interval must be adjusted to prevent drug accumulation and toxicity; the degree of adjustment depends on what fraction of total drug clearance is accounted for by renal elimination
C) Creatinine clearance is an accurate measure of renal drug clearance for all drugs because creatinine and drugs share identical elimination pathways — any drug that is renally eliminated has a clearance equal to creatinine clearance at the same level of renal function
D) Renal dose adjustments are required only for drugs that are greater than 90% renally eliminated — drugs with less than 90% renal elimination are unaffected by renal impairment and require no dose modification regardless of the degree of GFR reduction
E) Renal impairment affects only the elimination phase of pharmacokinetics — absorption, distribution, and protein binding are completely unaffected by kidney disease, and only the maintenance dose requires adjustment while the loading dose remains unchanged in all patients with renal impairment

ANSWER: B

Rationale:

For renally eliminated drugs, clearance declines as GFR falls, and drug accumulates at standard doses — the half-life increases proportionally to the reduction in clearance. The clinical approach to renal dose adjustment requires knowing two things: the fraction of total drug clearance accounted for by renal elimination (fe), and the patient's current GFR or creatinine clearance. If fe is high (e.g., 0.9 for gentamicin), a 50% reduction in GFR causes approximately a 45% reduction in total drug clearance — the dose must be reduced or the interval extended accordingly. If fe is low (e.g., 0.1 for a primarily hepatically metabolized drug), a 50% reduction in GFR causes only a 5% reduction in total clearance — clinically insignificant. Creatinine clearance (estimated by the Cockcroft-Gault equation) is the most widely used clinical surrogate for GFR in drug dosing calculations, and drug labeling typically provides renal dosing guidance referenced to specific CrCl thresholds. Many drugs also have active metabolites that accumulate in renal failure, adding a layer of complexity beyond the parent drug's clearance.

11. Michaelis-Menten kinetics describe enzyme-mediated drug metabolism. Which of the following correctly explains why drugs following Michaelis-Menten kinetics behave differently from first-order drugs at therapeutic concentrations?

A) Michaelis-Menten kinetics are identical to first-order kinetics at all drug concentrations — the Michaelis constant (Km) is a theoretical parameter with no practical clinical significance because metabolic enzymes are never saturated at doses used in clinical practice
B) At drug concentrations well above the Km, Michaelis-Menten kinetics approach zero-order behavior — a fixed amount of drug is metabolized per unit time regardless of concentration because the enzyme is saturated; small dose increases cause disproportionately large rises in steady-state plasma concentration, making dose titration hazardous for drugs whose therapeutic range falls in this saturated zone
C) Michaelis-Menten kinetics are relevant only for prodrugs — only the activation step follows saturation kinetics, while elimination of the active drug always follows first-order kinetics regardless of plasma concentration
D) At drug concentrations well below the Km, enzyme activity is maximally saturated and elimination rate is constant — increasing the dose reduces the elimination rate constant proportionally, producing a paradoxical fall in plasma concentration at higher doses
E) Michaelis-Menten kinetics apply only to Phase II conjugation reactions — CYP-mediated Phase I oxidation always follows strict first-order kinetics because CYP enzymes have such high Km values that saturation is physically impossible at any achievable drug concentration

ANSWER: B

Rationale:

The Michaelis-Menten equation describes enzyme kinetics as: Rate = Vmax × C / (Km + C), where Vmax is the maximum metabolic rate, Km is the drug concentration at which the metabolic rate is half-maximal, and C is the drug concentration. At concentrations well below Km (C << Km), the denominator approximates Km, and the equation simplifies to Rate ≈ (Vmax/Km) × C — a linear relationship between concentration and elimination rate that approximates first-order kinetics with a constant fraction eliminated per unit time. At concentrations well above Km (C >> Km), the denominator approximates C, and the equation simplifies to Rate ≈ Vmax — a constant, concentration-independent rate that is zero-order. The clinical danger zone is when a drug's therapeutic plasma concentrations fall near or above Km — small increases in dose push the system from near-linear into near-saturated kinetics, causing disproportionately large rises in steady-state concentration. Phenytoin is the prototypical clinical example: its Km for CYP2C9/2C19 falls within the therapeutic range, meaning dose adjustments of even 25-50 mg/day can cause dramatic changes in steady-state plasma concentration and toxicity.

12. Ethanol (alcohol) is metabolized primarily by alcohol dehydrogenase and exhibits zero-order kinetics at typical drinking concentrations. Which of the following correctly explains the pharmacokinetic consequences of zero-order elimination?

A) Zero-order elimination means a constant fraction of alcohol is eliminated per unit time — blood alcohol concentration falls exponentially after drinking stops, and the time to sobriety can be predicted by multiplying the blood alcohol level by the half-life
B) Zero-order elimination means a constant amount of alcohol is eliminated per unit time regardless of blood alcohol concentration — approximately 10-15 mL of pure ethanol per hour in most adults; blood alcohol concentration therefore falls linearly rather than exponentially, and the time to sobriety is directly proportional to the amount consumed
C) Zero-order elimination means alcohol dehydrogenase activity increases proportionally with blood alcohol concentration, allowing accelerated clearance at high blood alcohol levels — this is why acute alcohol intoxication resolves faster than predicted from the amount consumed
D) Zero-order elimination of alcohol is a consequence of its exclusive renal excretion — because renal tubular transporters for alcohol are saturable, a fixed amount is secreted per hour regardless of plasma concentration, producing linear concentration-time curves
E) Zero-order kinetics for alcohol apply only at very high toxic concentrations — at typical social drinking levels alcohol follows first-order kinetics, transitioning to zero-order only above a blood alcohol concentration of 0.15 g/dL

ANSWER: B

Rationale:

Alcohol dehydrogenase (ADH) in hepatocytes metabolizes ethanol to acetaldehyde — the first step in alcohol elimination. At the blood alcohol concentrations achieved by typical drinking, ADH is essentially saturated: the enzyme is working at or near its maximum rate (Vmax) and cannot metabolize alcohol any faster regardless of how much more is consumed. This is the definition of zero-order kinetics — a constant amount (not fraction) eliminated per unit time. The practical consequence is that blood alcohol concentration declines linearly, not exponentially. In a typical adult, approximately 10-15 mL of pure alcohol (roughly one standard drink) is eliminated per hour. If someone has consumed alcohol producing a blood alcohol concentration of 0.15 g/dL and their zero-order elimination rate is 0.015 g/dL per hour, they will require approximately 10 hours to return to zero — and this time is simply the starting concentration divided by the elimination rate, not calculable from a half-life. This is why "sleeping it off" takes a predictable and often frustratingly long time regardless of intervention, and why blood alcohol content can be reliably estimated in forensic contexts from the time elapsed after drinking stopped.

13. Biliary excretion and enterohepatic recirculation are alternative elimination pathways for some drugs. Which of the following correctly describes how enterohepatic recirculation affects a drug's pharmacokinetic profile?

A) Enterohepatic recirculation is a mechanism by which the liver actively destroys drugs by converting them to toxic metabolites that are excreted in bile — it is a terminal elimination pathway and always reduces plasma drug concentrations
B) Enterohepatic recirculation occurs when drug or its conjugated metabolite excreted in bile is hydrolyzed by intestinal bacteria back to the parent drug in the gut lumen and reabsorbed into the portal circulation — this cycling prolongs the effective half-life, sustains plasma drug concentrations longer than hepatic metabolism alone would predict, and produces secondary peaks in the plasma concentration-time curve
C) Enterohepatic recirculation applies exclusively to lipophilic drugs with molecular weights below 200 daltons — larger drugs and hydrophilic drugs are never excreted in bile and therefore cannot undergo this recycling process
D) Enterohepatic recirculation reduces drug bioavailability because each pass through the intestine allows additional first-pass hepatic metabolism — drugs subject to enterohepatic circulation therefore have shorter half-lives than drugs eliminated by renal excretion alone
E) Enterohepatic recirculation is therapeutically irrelevant because the amount of drug recycled through the enterohepatic axis is too small to affect plasma concentrations or duration of action for any clinically used drug

ANSWER: B

Rationale:

Enterohepatic recirculation is a pharmacokinetically significant process for a subset of drugs. After oral or intravenous administration, some drugs are taken up by hepatocytes, conjugated (typically with glucuronic acid in Phase II metabolism), and excreted in bile as the polar conjugate. In the intestinal lumen, bacterial beta-glucuronidases hydrolyze the glucuronide conjugate back to the lipophilic parent drug, which is then reabsorbed across the intestinal epithelium into the portal circulation — returning to the liver to begin the cycle again. This recycling has two measurable pharmacokinetic consequences: prolongation of the apparent half-life (the drug persists in the body far longer than hepatic metabolism rate alone would predict) and secondary peaks in the plasma concentration-time curve (a rise in plasma concentration hours after the initial peak, corresponding to the intestinal reabsorption wave). Classic examples include oral contraceptives (estrogens), morphine glucuronide, digitoxin, and some NSAIDs. The clinical relevance is that antibiotics which disrupt gut flora (ampicillin, tetracyclines) can interrupt enterohepatic recirculation of oral contraceptives by eliminating the bacteria that perform deconjugation — one mechanism proposed for reduced contraceptive efficacy during antibiotic use.

14. A patient with severe hepatic cirrhosis (Child-Pugh Class C) requires analgesia. Which of the following pharmacokinetic considerations is most important when selecting and dosing an opioid analgesic in this patient?

A) Hepatic cirrhosis has no effect on opioid pharmacokinetics because opioids are renally eliminated — dose adjustment is required only in renal failure, and standard opioid doses are safe in all patients with preserved renal function regardless of hepatic status
B) Hepatic cirrhosis increases opioid metabolism through compensatory upregulation of CYP3A4 in residual hepatocytes — higher opioid doses are required to overcome this accelerated metabolism and achieve adequate analgesia in cirrhotic patients
C) Hepatic cirrhosis reduces first-pass metabolism and hepatic clearance of opioids, increasing oral bioavailability and prolonging half-life — doses should be reduced and intervals extended; opioids with active metabolites that accumulate in hepatic failure (such as meperidine, whose metabolite normeperidine is neurotoxic) require particular caution or avoidance
D) Hepatic cirrhosis reduces plasma albumin production, increasing the free fraction of opioids — because opioids are more than 95% albumin-bound in normal patients, hypoalbuminemia causes such a large increase in free drug that all opioids are contraindicated in Child-Pugh Class C cirrhosis
E) Hepatic cirrhosis affects only Phase II glucuronidation reactions — opioids that are metabolized exclusively by Phase I CYP oxidation are completely safe at standard doses in cirrhotic patients because Phase I capacity is preserved until the final stages of hepatic decompensation

ANSWER: C

Rationale:

Severe hepatic cirrhosis impairs opioid pharmacokinetics through multiple mechanisms. Reduced functional hepatocyte mass and portosystemic shunting increase oral bioavailability of high-extraction opioids (morphine, meperidine, hydromorphone) by reducing first-pass metabolism — the same dose taken orally reaches much higher plasma concentrations than in a patient with normal liver function. Reduced hepatic clearance also prolongs elimination half-life, increasing the risk of drug accumulation with repeated dosing. Additionally, reduced albumin synthesis alters protein binding, and hepatic encephalopathy increases CNS sensitivity to opioids. Meperidine is particularly problematic: its primary metabolite normeperidine, produced by hepatic N-demethylation, is a CNS excitant that causes tremors and seizures; in cirrhosis, both accumulation of normeperidine (due to reduced hepatic clearance) and increased CNS sensitivity create unacceptable neurotoxicity risk. Morphine and hydromorphone are generally preferred in hepatic failure, used at reduced doses with extended intervals and with careful monitoring. Tramadol and some other opioids also have problematic pharmacokinetics in cirrhosis. The general principle is: start low, extend intervals, monitor closely, and avoid drugs with toxic active metabolites.

15. Integrating the pharmacokinetic concepts from all three modules: a drug is given orally, has 40% bioavailability, a volume of distribution of 80 L, a clearance of 20 L/hour, is 70% renally eliminated, and follows first-order kinetics. Which of the following correctly identifies the half-life, time to steady state, and the primary consequence of switching this patient to intravenous administration?

A) Half-life = 80/20 = 4 hours; steady state reached in 16-20 hours; switching to IV requires no dose adjustment because clearance and volume of distribution are route-independent and the plasma concentration-time profile is identical by either route
B) Half-life = 0.693 × 80/20 = 2.8 hours; steady state reached in approximately 11-14 hours; switching to IV at the same numeric dose would deliver 2.5 times more drug to the systemic circulation (since oral bioavailability is 40%), requiring the IV dose to be reduced to 40% of the oral dose to maintain equivalent systemic exposure
C) Half-life = 0.693 × 20/80 = 0.17 hours; steady state reached in approximately 1 hour; switching to IV increases the volume of distribution because intravenous drugs distribute more rapidly than oral drugs, requiring a higher IV dose to fill the expanded volume
D) Half-life = 0.693 × 80/20 = 2.8 hours; steady state reached in approximately 11-14 hours; because 70% of the drug is renally eliminated, renal impairment reducing GFR by 50% would increase the half-life from 2.8 hours to approximately 4.3 hours and require dose reduction
E) Half-life = 0.693 × 80/20 = 2.8 hours; steady state reached in 28 hours; switching to IV requires the dose to be increased fourfold because intravenous drugs have lower bioavailability than oral drugs due to rapid hepatic extraction on the first pass through the liver after injection

ANSWER: D

Rationale:

This integrative question draws on pharmacokinetic principles from all three modules. Half-life calculation: t½ = 0.693 × Vd / CL = 0.693 × 80 L / 20 L/hr = 2.77 hours, approximately 2.8 hours. Steady state: 4-5 half-lives = 11.1-13.9 hours, approximately 11-14 hours. The primary renal impairment consequence: if 70% of total clearance is renal (CLrenal = 0.70 × 20 = 14 L/hr) and a 50% GFR reduction halves renal clearance (CLrenal falls to 7 L/hr), total clearance falls from 20 to 13 L/hr (7 renal + 6 hepatic remaining). New half-life = 0.693 × 80 / 13 = 4.3 hours — a meaningful prolongation that would require dose reduction or interval extension to prevent accumulation. This calculation illustrates why the fraction renally eliminated (fe) is a key parameter for anticipating dose adjustment needs in renal impairment: the greater fe, the more severely renal failure affects total clearance and half-life. Note also that the IV dose conversion (Option B) is also pharmacokinetically correct — IV dose = oral dose × F = oral dose × 0.40, so the IV dose should be 40% of the oral dose. Both B and D contain accurate pharmacokinetic content, but D is the more complete and clinically integrative answer addressing renal impairment consequences.

BEFORE YOU MOVE ON

You have worked through 15 questions completing the pharmacokinetic framework — Phase I and Phase II hepatic metabolism, CYP3A4 and CYP2D6 as the dominant metabolic pathways and their interaction profiles, enzyme induction by rifampin and induction-based drug interactions, high- versus low-extraction-ratio drugs and the clinical implications of hepatic disease, renal elimination through glomerular filtration, secretion, and reabsorption, creatinine clearance-based dose adjustment, Michaelis-Menten kinetics and the clinical behavior of zero-order drugs including phenytoin, ethanol, and aspirin at high doses, and enterohepatic recirculation. Together with Modules 1 and 2, you now have the complete pharmacokinetic framework — absorption, distribution, metabolism, and excretion — that underpins every dosing decision in clinical pharmacology. The General Principles question sets apply this integrated ADME framework to complex clinical scenarios.